FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1006-1007 October 12, 1995 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Warkentin, T. E.

To the Editor: We disagree that the study by Warkentin et al. (May 18 issue)¹ identified a difference in outcome favoring the use of low-molecular-weight heparin. Their initial study of the identical patient population found no statistically significant difference in thrombotic events, incidence of venous thrombosis, episodes of major bleeding, or red-cell–transfusion requirements between the group given standard heparin and the group given low-molecular-weight heparin.²

From both studies (really the same study) one can conclude only that heparin-induced thrombocytopenia is a marker of thrombotic disease, because the authors do not demonstrate that thrombosis as a consequence of heparin-induced thrombocytopenia has . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.